MSG Team's other articles

9805 Implementation of ERP System – Reengineering vs Customization, Big Bang or Phased Implementation

Implementation of ERP System, is a complex exercise, involving many process alterations and several legacy issues. Organizations need a implementation strategy encompassing both pre implementation and implementation stages. The fallout of a poor strategy is unpreparedness of employees, implementation not in conformity with wider business strategy, poor business process redesign and time and cost overrun. […]

11037 Risk Mitigation Team and their Role in Business Continuity Management

In previous articles, we have seen how Business Continuity Programs are formulated and how they are executed in times of crisis. In this article, we look at the role of the Risk Management and Risk Mitigation Team in aiding the organization towards formulating contingency planning. The risk management team is responsible for identifying risks, coming […]

11253 Internal Technology Framework: 7S Framework

Introduction In the modern age of cutting-edge technology and continuous innovation, product life cycle is ever shortening. There is constant pressure on companies to differentiate from competition and earn customer satisfaction. In such a business environment, it is essential that internal organization network is strong and efficient to deal with any kind of changes. The […]

11977 Why Growth is Stalling around the World?

Why is Growth Stagnant? We read in the print and online media about why governments worldwide are unable to revive growth especially since the Great Recession of 2008. We also read how policymakers are trying their best to jumpstart growth but are being unable to do so. Moreover, we see stock markets going up while […]

9471 Develop a Goal Statement corresponding to the Problem Statement

A six sigma team is meant to concentrate on the solutions and not on the problems. It is for this reason that once the problem has been identified, it must be quickly turned in to a goal statement that will guide the execution of the project. What is a Goal Statement ? The Problem statement […]

Search with tags

  • No tags available.

The Case for Patents

The Pharma sector is often caught in the fight over whether the enforcement of IPR or Intellectual Property Rights should be followed or whether the sector exists for alleviating the health concerns of the poor and the needy thereby ensuring affordable drugs to the masses.

Before we launch into the discussion of the pros and cons of this debate, we must first examine the issues at hand. It is indeed the case that the Pharma sector spends huge amounts of money in research and development of new drugs which are then priced at rates that let them recoup the investment as well as make profits.

Further, the current sociopolitical and legal thinking in the United States and the West is that since the Pharma sector spends a lot on R&D, they must be allowed to patent the drugs that they develop and ensure that competitors cannot copy or produce the same drugs. This is the basic legal position in most parts of the world where the idea is to incentivize and encourage the Pharma companies to come out with better drugs by patenting those inventions and pricing them accordingly.

The Case against Patents

However, this line of thinking has not been followed in the Third World where the governments insist that the Pharma companies can only patent the processes by which they manufacture the drugs and not the underlying product. This means that any competitor can make the same formulaic drugs using a different process thereby ensuring price fairness due to market competition.

The rationale for this thinking is that most of the Third World steeped in poverty cannot afford the high prices for drugs especially when the majority of their citizens who are often poor and needy are in desperate need of lifesaving drugs at affordable prices. This is the other side of the issue which the Western Pharma majors have objected to since they lose the monopoly over their drugs that are patented and in whom they have invested substantial amounts of money.

Indeed, with globalization and the opening up of many developing countries to Western companies in the 1990s, the various agreements under the WTO (World Trade Organization) such as GATT (General Agreement on Tariffs and Trade) required the signatory countries to dismantle protectionist regimes as well as to let the drugs be patented not only for the processes but also the products.

Debating the Issue

If we examine these two sides of the debate, it is indeed clear that both positions are strong and have valid points.

For instance, the case for patents and their protection is strong since the Pharma majors invest in R&D and drug trials and the time to market is indeed long. However, on the other hand, the developing world also needs their concerns to be take care of since they have not reached a stage where their people can afford medication that is prohibitively expensive.

The fact that the rampant spread of HIV (Human Immune Virus) among the Third World countries is the strongest argument for leaving out the drugs to treat them from patenting and thereby ensuring cheaper access to the people for such drugs.

Therefore, what we have is that a situation has been created wherein there is a heated debate between the proponents of patents and its opponents with neither side willing to back down from their positions. This calls for some serious dialogue between them as well as for the governments of the world to come out with steps wherein both the Pharma companies and their citizens win in the bargain.

Some Possible Solutions

For this to happen, both parties must be willing to concede ground and back down from brinkmanship. This can take the form of the Pharma companies cross subsidizing the expensive drugs especially those that treat life threatening conditions.

Further, they can also agree to a patent protection regime of five or ten years instead of the sometimes lifetime and sometimes decades long protection which they have at the moment.

Apart from this, there can be better cooperation between the various Pharma companies so that they undertake Pro Bono selling by differential pricing in their home countries and in the Third World. The latter in turn can encourage their domestic companies to invest more in R&D and not just copy the drugs made in the West which is the case in many of the Third World countries. Moreover, they can offset some of the losses of the Western Pharma majors by absorbing some of the costs and letting the poor and the needy benefit in the process. Both these strategies are currently being followed in India where the government subsidizes the HIV drugs in addition to many drugs that cater to life threatening conditions.

Conclusion

Perhaps the most optimal solution would be from the Pharma sector itself which again using the example of India wherein many Indian Pharma majors often price their drugs in such a manner as to benefit the poor.

Of course, the flipside is that unless the governments of the Third World countries make healthcare a right and ensure that their commitment is not only in speeches and instead, they walk the talk by improving the conditions in the hospitals and making generics as well as patented drugs affordable, the fight between the stakeholders would not be resolved.

In conclusion, the Pharma sector is too critical to be left alone to the whims of the market and therefore, there is an urgent need for all stakeholders to actualize strategies that would benefit the poor and the needy.

Article Written by

MSG Team

An insightful writer passionate about sharing expertise, trends, and tips, dedicated to inspiring and informing readers through engaging and thoughtful content.

Leave a reply

Your email address will not be published. Required fields are marked *

Related Articles

The Problem of Piracy and Intellectual Property Rights

MSG Team

Introduction to Intellectual Property Rights

MSG Team